Under the three year agreement, Baxter Healthcare will provide the MOH with 16 million doses of the influenza vaccine in case of a national pandemic. That is enough to treat the entire population of the country.
Baxter is also under contract to provide 2 million doses of H5N1 vaccine to the United Kingdom government, and is in talks with the U.S. National Institute of Allergy and Infectious Diseases to develop a cell based culture H5N1 vaccine.
The increasing interest in Baxter's vaccine was motivated by phase I/II clinical results of its inactivated wild-type H5N1 pandemic vaccination of 270 patients last month. The vaccine was shown to be well tolerated in humans.
Baxter now needs to carry out a much larger vaccination trial to prove its effectiveness in a wider and more diverse population of test subjects.
Shares of Baxter closed on Tuesday at $44.90, near its 52-week high of $47.49 reached just last month.
BAX 1-yr chart: